Human leukocyte antigen class I alleles and the risk of chronic myelogenous leukemia: a meta-analysis

References

• Naugler C, Liwski R. HLA risk markers for chronic myelogenous leukemia in Eastern Canada. Leuk Lymphoma 2009;50:254–259.
   PubMed Web of Science ®Google Scholar
• Pinilla-Ibarz J, Cathcart K, Scheinberg DA. CML vaccines as a paradigm of the specific immunotherapy of cancer. Blood Rev 2000;14:111–120.
   PubMed Web of Science ®Google Scholar
• Schmitt M, Li L, Giannopoulos K, et al Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules. Exp Hematol 2006;34:1709–1719.
   PubMed Web of Science ®Google Scholar
• Oguz FS, Kalayoglu S, Diler AS, et al HLA system affects the age-at-onset in chronic myeloid leukemia. Am J Hematol 2003;73:256–262.
   PubMed Web of Science ®Google Scholar
• Dorak MT, Chalmers EA, Gaffney D, et al Human major histocompatibility complex contains several leukemia susceptibility genes. Leuk Lymphoma 1994;12:211–222.
   PubMed Web of Science ®Google Scholar
• Liu J-B, Li M, Chen H, et al Association of vitiligo with HLA-A2: a meta analysis. J Eur Acad Dermatol Venereol 2006;2:205–213.
   Google Scholar
• Delgato-Vega AM, Anaya JM. Meta-analysis of HLA-DRB1 polymorphism in Latin American patients with rheumatoid arthritis. Autoimmun Rev 2007;6:402–408.
   PubMed Web of Science ®Google Scholar
• Stokkers PCF, Reitsma PH, Tygat GNJ, et al HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta analysis. Gut 1999;45:395–401.
   PubMed Web of Science ®Google Scholar
• Chhaya SU. Human leukocyte antigens in Indian patients with chronic myeloid leukemia. Leuk Lymphoma 2006;47:291–295.
   PubMed Web of Science ®Google Scholar
• Miao KR, Pan QQ, Xue M, et al Human leukocyte antigens in 295 Chinese patients with chronic myeloid leukemia. Leuk Lymphoma 2007;48:2152–2156.
   PubMed Web of Science ®Google Scholar
• Wei L, Xiao LL, Wu XY, et al [Expression and analysis of HLA-A, B and DRB1 genes in patients with chronic myelogenous leukemia in Guangdong area]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2008;16:915–918.
   PubMedGoogle Scholar
• Li D, Xi B, Liu HY, Yu Y. [Association of gene HLA-class I with leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2005;13:563–566.
   PubMedGoogle Scholar
• Posthuma EF, Falkenburg JH, Apperley JF, et al HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. Blood 1999;93:3863–3865.
   PubMed Web of Science ®Google Scholar
• Ruuska P, Silvennoinen-Kassinen S, Timonen T, Tiilikainen A. Chronic myelocytic leukaemia: HLA association and decreased erythrocyte C3b receptor expression. Clin Exp Immunol 1985;59:300–304.
   PubMed Web of Science ®Google Scholar
• Review Manager (RevMan) version 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2003.
   Google Scholar
• Bocchia M, Wentworth PA, Southwood S, et al Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995;85:2680–2684.
   PubMed Web of Science ®Google Scholar
• Greco G, Fruci D, Accapezzato D, et al Two brc-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes. Leukemia 1996;10:693–699.
   PubMed Web of Science ®Google Scholar
• Buzyn A, Ostankovitch M, Zerbib A, et al Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. Eur J Immunol 1997;27:2066–2072.
   PubMed Web of Science ®Google Scholar
• Barrett J, Guimaraes A, Cullis J, Goldman JM. Immunological characterization of the tumor-specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukemia. Stem Cells 1993;11:104–108.
   PubMed Web of Science ®Google Scholar
• Cullis JO, Barrett AJ, Goldman JM, Lechler RI. Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen-processing defective cell lines. Leukemia 1994;8:165–170.
   PubMed Web of Science ®Google Scholar
• Kessler JH, Bres-Vloemans SA, van Veelen PA, et al BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T cell epitopes. Leukemia 2006;20:1738–1750.
   PubMed Web of Science ®Google Scholar
• Rezvani K, Grube M, Brenchley JM, et al Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003;102:2892–2900.
   PubMed Web of Science ®Google Scholar
• Cathcart K, Pinilla-Ibarz J, Korontsvit T, et al A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004;103:1037–1042.
   PubMed Web of Science ®Google Scholar
• Yotnda P, Firat H, Garcia-Pons F, et al Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998;101:2290–2296.
   PubMed Web of Science ®Google Scholar
• Molldrem JJ, Lee PP, Kant S, et al Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest 2003;111:639–647.
   PubMed Web of Science ®Google Scholar
• Molldrem JJ. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000;6:1018–1023.
   PubMed Web of Science ®Google Scholar
• Bellantuono I, Gao L, Parry S, et al Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 2002;100:3835–3837.
   PubMed Web of Science ®Google Scholar
• Gannage M, Abel M, Michallet AS, et al Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol 2005;174:8210–8218.
   PubMed Web of Science ®Google Scholar
• Maslak PG, Dao T, Gomez M, et al A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease. Leukemia 2008;22:1613–1616.
   PubMed Web of Science ®Google Scholar